Who We Are
We are founded and led by pioneers in AI-driven drug discovery and targeted protein degradation, with fully-equipped labs in Stevenage and our HQ in London.
Our expertise has led to the successful delivery of multiple clinical candidates across a range of diseases, advancing innovative treatments through cutting-edge technology.
Our AI solutions have transformed drug discovery, with proven success in structural biology, knowledge graphs, and target assessment. With numerous patents and publications in structural bioinformatics, medicinal chemistry, and chemical biology, we continue to push the boundaries of scientific innovation.
Our Team
-
![Headshot of Chris Tame]()
Dr Chris Tame
CEO and Founder
-
![Headshot of Andrew Potterton]()
Dr Andrew Potterton
CTO
-
![Headshot of Rosa Cookson]()
Dr Rosa Cookson
Chemical Biology
-
![Headshot of Adam Yip]()
Dr Adam Yip
Medicinal Chemistry
-
![Headshot of Dom Lukauskis]()
Dr Dom Lukauskis
Computational Chemistry
-
![Headshot of Naail Kashif-Khan]()
Dr Naail Kashif-Khan
Computational Chemistry
-
![]()
Sarah Griffiths
In Vitro Biologist
-
![]()
Sue Foxall
In Vitro Biologist
Our Advisors
-
![Headshot of Fergus Imrie]()
Dr Fergus Imrie
Fellow, Oxford University
Expert in Machine Learning for Drug Discovery
-
![Headshot of Katrin Rittinger]()
Prof Katrin Rittinger
Group Leader, Francis Crick Institute
E3 ligase expert
-
![Headshot of Ivan Griffin]()
Dr Ivan Griffin
BenevolentAI Founder and COO
AI in drug discovery pioneer
-
![Headshot of Krista Goodman]()
Dr Krista Goodman
Larkspur Bio CSO
Leader in Chemistry and Precision Medicine
-
![Headshot of John Harling]()
Dr John Harling
ex-GSK Head of Modalities
Targeted Protein Degradation pioneer
Our Funding
The start-up is backed by two European based venture funds, Pace Ventures and I&I Bio, which invests in innovative European life science companies focused on drug discoveries, medical devices, diagnostics, and digital health.
Contact us
Interested in working together? Fill out some info and we will be in touch shortly.